Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 238-692-3 | CAS number: 14643-87-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / bone marrow chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- From April 29, 1986 to August 05, 1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 475 (Mammalian Bone Marrow Chromosome Aberration Test)
- Deviations:
- not specified
- Principles of method if other than guideline:
- An in vivo bone marrow chromosomal aberration assay was conducted with rats. Chromosome aberrations were analyzed (5 animals per sex, 50 metaphases per animal) at 6, 12, and 24 h after oral gavage doses of 100, 333 or 1000 mg/kg bw.
- GLP compliance:
- yes
- Type of assay:
- other: Chromosome aberration assay
Test material
- Reference substance name:
- Reference substance 001
- Cas Number:
- 79-10-7
- Molecular formula:
- C3H4O2
- Details on test material:
- - Name of test material (as cited in study report): CJP-60
- Source: Hoechst Celanese Company (according to McCarthy et al., 1992)
- Analytical purity: >99.8 %
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Raleigh, North Carolina
- Age at study initiation: 6-7 weeks of age
- Weight at study initiation: 142-177 g (males), 132-164 g (females)
- Housing: singly
- Diet: ad libitum
- Water: ad libitum
- Assigned to test groups randomly: yes
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Photoperiod (hrs dark / hrs light): 12 hrs/12 hrs
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: water
- Concentration of test material in vehicle:
- Amount of vehicle (if gavage or dermal): - Duration of treatment / exposure:
- One treatment by gavage
- Frequency of treatment:
- Once
- Post exposure period:
- At the time specified following dosing in the acute dosing regime, the rats received an intraperitoneal injection of colchicine (1.0 mg/kg bw) based on terminal weight to arrest mitosis. 2-4 hrs later the animals were sacrificed.
Doses / concentrations
- Remarks:
- Doses / Concentrations: 100, 333, and 1000 mg/kg bw (in a total volume of 3 mL/kg bw)
Basis: actual ingested
- No. of animals per sex per dose:
- 5 animals/sex/dose/sacrifice time
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide
- Route of administration: gavage
- Doses / concentrations: 10 mg/mL
Examinations
- Tissues and cell types examined:
- Bone marrow cells from the femur
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
Dose levels for the in vivo cytogenetic assay were selected on the basis of body weight changes, gross observations, and mortality in a preliminary toxicity test. The results of the preliminary toxicity test led to the selection of 1000 mg/kg body weight as the maximum dose for the acute assay. Also a preliminary assessment of bone marrow cell cycle kinetics at 900 mg/kg bw indicated no significant cell cycle delay at 21 hr after dosing.
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields): at 6, 12, and 24 hours after dose administration
DETAILS OF SLIDE PREPARATION: At least three slides from each animal were prepared. Stain: Giemsa
METHOD OF ANALYSIS: 50 metaphase spreads for each animal were scored. The mitotic index for each animal was determined.
Each metaphase figure was scored for the following items:
1. Number of chromosomes in each metaphase figure.
2. Gaps - Achromatic region in chromatid no greater than the width of the chromatid.
3. Chromatid breaks - Achromatic region in the chromatid greater than the wigth of the chromatid or where the broken piece is misaligned with the rest of the arm.
4. Chromosome breaks - Achromatic region in both chromatids at the same locus with marked displacement of both distal fragments.
5. Fragments - Chromatid(s) not containing a centromere. May be seen in association or not in association with a parent chromatid.
6. Exchange figure - Chromatid interchange involving two or more chromosomes, with either symmetrical or asymmetrical distortion of the usual chromatid pattern.
7. Dicentric - Chromosome with two centromeres.
8. Ring - Chromosome whose ends have joined to form a double or single circle, with or without a centromere.
9. Polyploid - Increase in chromosome number in excess of the diploid and in multiple of the haploid number.
10. Pulverization - Extreme fragmentation of the chromatid material.
11. Severely damaged cell - Cell with ten or more abberations of any type or with pulverization. - Evaluation criteria:
- The test substance is considered to induce a positive response when the number of aberrations per cell is significantly increased (p <= 0.05, Student's t-test) relative to the vehicle control. A significant increase at the high dose only with no dose-response also is considered positive. A significant increase at one dose other than the high dose with no dose-response is considered equivocal.
- Statistics:
- The t-test was used to compare pairwise the number of aberrations per cell of each treated group with that of the vehicle control. Each comparison was considered to be between two independent, random samples of unequal variance and a significant increase in the treatment mean relative to the vehicle control (one-sided) was sought.
Results and discussion
Test results
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- - Dose range: 0, 700, 900, 1100, and 1300 mg/kg bw (male); 0, 600, 800, 1000, and 1200 mg/kg bw (female)
- Solubility: completely soluble
- Clinical signs of toxicity in test animals: One female rat in the 1200 mg/kg bw dose group and one male rat in the 900 mg/kg bw group were found dead approximately 72 hours following dose administration. A reduction in body weight gain was observed in all test article treated rats 24 hours after dose administration and persisted up to 72 hours in male rats that received 1200 and 1000 mg/kg bw. Clinical signs of toxicity observed included lethargy, irregular breathing (including wheezing and sneezing), lacrimation, crusty eyes, excessive salivation, and nasal discharge. Based on these results and previous LD50 data, 1000 mg/kg bw was selected as high dose.
- Harvest times: 6, 12, and 24 hours
Any other information on results incl. tables
Mortality and Clinical signs:
A moderate reduction in weight gain was observed on day 1 after dose administration in male and female rats that received 1000 mg/kg bw of test substance. Two female animals, one that received 1000 mg/kg bw and one that received 333 mg/kg bw, were found dead prior to their scheduled sacrifice. Irregular breathing and wheezing were noted in three females from the 1000 mg/kg bw group. All other animals appeared normal over the course of the study period.
Chromosomal damage in bone marrow of male rats following acute exposure to acrylic acid:
Treatment [mg/kg bw] |
Time [hr] |
Total no. of cells |
Incidence of aberrations1[%] |
Total no. of aberrations |
Aberrations from severely damaged cells3 |
Aberrations/cell1 |
|||
|
evaluated |
with aberrations1 |
|
gaps |
breaks2 |
rearrangements |
|
|
|
Water |
6 |
250 |
0 |
0.0 |
3 |
0 |
0 |
0 |
0.000±0.000 |
(3 mL/kg) |
12 |
250 |
1 |
0.4 |
0 |
1 |
0 |
0 |
0.004±0.009 |
|
24 |
250 |
0 |
0.0 |
0 |
0 |
0 |
0 |
0.000±0.000 |
|
|
|
|
|
|
|
|
|
|
TS 1000 |
6 |
250 |
1 |
0.4 |
1 |
1 |
0 |
0 |
0.004±0.009 |
|
12 |
250 |
0 |
0.0 |
0 |
0 |
0 |
0 |
0.000±0.000 |
|
24 |
250 |
1 |
0.4 |
1 |
1 |
0 |
0 |
0.004±0.009 |
|
|
|
|
|
|
|
|
|
|
TS 333 |
6 |
250 |
2 |
0.8 |
2 |
2 |
0 |
0 |
0.008±0.011 |
|
12 |
250 |
1 |
0.4 |
1 |
1 |
0 |
0 |
0.004±0.009 |
|
24 |
250 |
0 |
0.0 |
1 |
0 |
0 |
0 |
0.000±0.000 |
|
|
|
|
|
|
|
|
|
|
TS 100 |
6 |
250 |
1 |
0.4 |
0 |
1 |
0 |
0 |
0.004±0.009 |
|
12 |
250 |
1 |
0.4 |
0 |
1 |
0 |
0 |
0.004±0.009 |
|
24 |
250 |
0 |
0.0 |
0 |
0 |
0 |
0 |
0.000±0.000 |
|
|
|
|
|
|
|
|
|
|
CP 30 |
24 |
250 |
98 |
39.2** |
0 |
172 |
67 |
390 |
2.516±0.599** |
1: Excluding gaps.
2: Includes chromatid and chromosome breaks and fragments.
3: Cells having more than 10 aberrations were counted as 10.
* p<0.05; ** p<0.01
CP: cyclophosphamide
Chromosomal damage in bone marrow of female rats following acute exposure to acrylic acid:
Treatment [mg/kg bw] |
Time [hr] |
Total no. of cells |
Incidence of aberrations1[%] |
Total no. of aberrations |
Aberrations from severely damaged cells3 |
Aberrations/cell1 |
|||
|
evaluated |
with aberrations1 |
|
gaps |
breaks2 |
rearrangements |
|
|
|
Water |
6 |
250 |
1 |
0.4 |
0 |
1 |
0 |
0 |
0.004±0.009 |
(3 mL/kg) |
12 |
250 |
1 |
0.4 |
2 |
1 |
0 |
0 |
0.004±0.009 |
|
24 |
250 |
0 |
0.0 |
0 |
0 |
0 |
0 |
0.000±0.000 |
|
|
|
|
|
|
|
|
|
|
TS 1000 |
6 |
250 |
0 |
0.0 |
1 |
0 |
0 |
0 |
0.000±0.000 |
|
12 |
250 |
0 |
0.0 |
1 |
0 |
0 |
0 |
0.000±0.000 |
|
24 |
250 |
0 |
0.0 |
0 |
0 |
0 |
0 |
0.000±0.000 |
|
|
|
|
|
|
|
|
|
|
TS 333 |
6 |
250 |
1 |
0.4 |
1 |
1 |
0 |
0 |
0.004±0.009 |
|
12 |
250 |
0 |
0.0 |
0 |
0 |
0 |
0 |
0.000±0.000 |
|
24 |
250 |
0 |
0.0 |
0 |
0 |
0 |
0 |
0.000±0.000 |
|
|
|
|
|
|
|
|
|
|
TS 100 |
6 |
250 |
1 |
0.4 |
1 |
1 |
0 |
0 |
0.004±0.009 |
|
12 |
250 |
1 |
0.4 |
0 |
1 |
0 |
0 |
0.004±0.009 |
|
24 |
250 |
1 |
0.4 |
0 |
1 |
0 |
0 |
0.004±0.009 |
|
|
|
|
|
|
|
|
|
|
CP 30 |
24 |
250 |
83 |
32.2** |
1 |
105 |
72 |
3104 |
1.948±0.854** |
1: Excluding gaps.
2: Includes chromatid and chromosome breaks and fragments.
3: Cells having pulverization or > 10 aberrations of any type.
4: Includes 10 aberrations contributed by 1 pulverized cell.
* p<0.05; ** p<0.01
CP: cyclophosphamide
Applicant's summary and conclusion
- Conclusions:
- Under the study conditions, the test substance was not considered to be genotoxic to rat by oral administration in chromosomal aberration assay.
- Executive summary:
A study was conducted to determine the ability of the test substance to induce chromosomal aberrations in rats, according to a method similar to OECD Guideline, in compliance with GLP. The test substance doses were 100, 333, and 1000 mg/kg bw (in a total volume of 3 mL/kg bw) administered by oral gavage a single time. These doses were selected based on the range finding study. Cyclophosphamide positive control group received a single oral dose of mg/mL. A moderate reduction in weight gain was observed on Day 1 after dose administration in male and female rats that received 1000 mg/kg bw of test substance. Two female animals, one that received 1000 mg/kg bw and one that received 333 mg/kg bw, were found dead prior to their scheduled sacrifice. Irregular breathing and wheezing were noted in three females from the 1000 mg/kg bw group. All other animals appeared normal over the course of the study period. Of the 250 metaphase bone marrow cells examined from each animal, no significant increase in chromatid and chromosome breaks or structural rearrangements were noted for test substance. The results of the study indicate that test substance at these dose levels did not induce detectable chromosomal aberrations after oral administration. Under the study conditions, the test substance was not considered to be genotoxic to rat by oral administration in chromosomal aberration assay (Celanese, 1986).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.